Scientists launch global effort to map rare brain disorders

NCT ID NCT07372833

First seen Feb 01, 2026 · Last updated Jun 24, 2026 · Updated 18 times

Summary

This study follows 150 children and adults worldwide who have a rare genetic condition affecting CAMK2 genes. Researchers will track development, seizures, behavior, and social skills over time. The goal is to create a clear picture of how the disorder progresses, which can help doctors give better care and prepare for future treatment trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAMK2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Erasmus MC

    RECRUITING

    Rotterdam, South Holland, 3015 GD, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study will create detailed maps of how CAMK2 disorders progress, helping doctors predict outcomes and design better treatments.

What could go wrong

This is an observational study, not a treatment trial. It collects data only and cannot directly improve symptoms. Results may take years to influence care.

Conditions

The condition(s) this trial relates to.

CAMK2D-related neurodevelopmental disorder and dilated cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.